The following is a physician-patient interaction that took place within TheBody.com's "Ask the Experts" forum on hepatitis.
|will hvc treament affect my female fertility
Apr 13, 2013
I have a low vilal load hvc genotype 1 will triple therapy with incivek interfuron and ribiviran have a negative impact on my fertility I'm a 25 yr female with no kids?
| Response from Dr. Taylor
There is no evidence to suggest that the treatments you mention, have any impact on your fertility. So you should be fine regarding your fertility. With a low hep C viral load and triple therapy, you have an excellent chance of cure.
However, interferon and ribavirin are not safe medications to take during pregnancy.
These medications can last in the body for a long time so it is recommended that a person wait at least 6 months after stopping these medications to become pregnant. I recommend waiting at least 9 months after stopping these medications before becoming pregnant, a year if possible. Ribavirin can cause damage to a developing fetus. Interferon may increase risks for spontaneous loss of pregnancy. So regarding your timeline for becoming pregnant, factor in needing at least 9 months after taking ribavirin to attempt pregnancy, and protect yourself from becoming pregnant during and for the months after hep C treatment.
Return to our full listing of answers to patients' frequently asked questions regarding hepatitis C transmission, testing, management and treatment.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Evidence of Accelerated Brain Aging in HIV-Positive People on Effective ART|
|Final HIV Research Highlights From CROI 2017|
|With Possibilities for Long-Acting HIV Treatment, Modern Science Creates Modern ART|
|Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study|
|No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study|
|Really Rapid Review -- CROI 2017, Seattle|